Oyster Point Pharma (NASDAQ:OYST – Get Rating) had its price target cut by analysts at Piper Sandler from $60.00 to $15.00 in a research report issued on Friday, The Fly reports. Piper Sandler’s price objective would suggest a potential upside of 271.29% from the stock’s current price. Separately, Zacks Investment Research upgraded shares of Oyster […]
Oyster Point Pharma (NASDAQ:OYST – Get Rating) and Qiagen (NASDAQ:QGEN – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends. Institutional & Insider Ownership 86.3% of Oyster Point Pharma shares […]
Oyster Point Pharma, Inc. (NASDAQ:NASDAQ:OYST) Q1 2022 Earnings Conference Call May 5, 2022, 4:30 PM ET Company Participants Arty Ahmed - Vice President, Investor Relations Dr.
Oyster Point Pharma (NASDAQ:OYST – Get Rating) posted its quarterly earnings data on Thursday. The company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.75) by ($0.05), Fidelity Earnings reports. During the same period last year, the business posted ($0.73) earnings per share. NASDAQ:OYST traded down $0.46 during mid-day […]